Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Sunday, October 1, 2023 · 658,958,866 Articles · 3+ Million Readers

With 10.4 % CAGR, Mucopolysaccharidosis Treatment Market Size worth USD 4.37 Billion in 2026

According to Fortune Business Insights, The Mucopolysaccharidosis Treatment Market size is anticipated to reach USD 4.37 Billion by 2026, the market size was USD 1.98 billion in 2018 and is anticipated to rise at a CAGR of 10.4%

/EIN News/ -- Pune, India, Nov. 15, 2022 (GLOBE NEWSWIRE) -- The global mucopolysaccharidosis treatment market size is predicted to reach USD 4.37 billion by 2026, exhibiting a CAGR of 10.4% during the forecast period. The growing cases of rare diseases can be critical factor in fuelling the demand for mucopolysaccharidosis treatment, which in turn, will aid the expansion of the market. Moreover, the increasing R&D investments by key players for new therapeutics will have a positive impact on the mucopolysaccharidosis treatment market growth. In addition, the growing awareness regarding the novel therapies to treat mucopolysaccharidosis will bolster healthy growth of the market during the forecast period.


Get a Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/mucopolysaccharidosis-treatment-market-102551


Report Scope:

Report Coverage Details
Forecast Period 2019 to 2026
Forecast Period 2019 to 2026 CAGR 10.4%
2026 Value Projection USD 4.37 billion
Base Year 2018
Market Size in 2018 USD 1.98 billion
Historical Data for 2015 to 2017
No. of Pages 150




Drivers and Restraints:

Unmet Clinical Needs to Influence Market Growth

The growing necessity for advanced therapeutics will impel companies to launch novel therapies, which in turn, will boost the mucopolysaccharidosis treatment market growth in the forthcoming years. Moreover, the growing unmet clinical needs of patients along with better treatment outcomes will spur demand for mucopolysaccharidosis treatment market during the forecast period. Moreover, the increasing acquisitions and deals between key players will bolster healthy growth of the market. For instance, in April 2019, GC Pharma announced the signing of a licensing deal with Clinigen KK in Japan for their product offering of Hunterase ICV, which is used for the treatment of Mucopolysaccharidosis Type II (Hunter syndrome). In addition, the increasing R&D by pharmaceutical companies for the mass production  of conventional medications or therapies to treat diseases such as heart disease and diabetes along with rare disorders such as the types of mucopolysaccharidosis. This factor will aid the mucopolysaccharidosis treatment market revenue in the foreseeable future.


Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit: https://www.fortunebusinessinsights.com/mucopolysaccharidosis-treatment-market-102551


Mucopolysaccharidosis Treatment Market Segments:

Market Segmentation By Treatment
  • Enzyme Replacement Therapy (ERT)
  • Others
By Disease Type
  • Mucopolysaccharidosis Type |
  • Mucopolysaccharidosis Type II
  • Mucopolysaccharidosis Type IV A
  • Mucopolysaccharidosis Type VI
  • Others
By Route of Administration
  • Intravenous
  • Intracerebroventricular (ICV)
By End User
  • Hospitals
  • Specialty Clinics
  • Others
By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/mucopolysaccharidosis-treatment-market-102551


Competitive Landscape:

Increasing Prevalence of Rare Diseases to Stimulate Growth in North America

The market in North America generated a revenue of USD 1,019.4 million in 2018. The growth in the region is attributed to the higher diagnosis and treatment rates for a number of rare disorders. The favorable reimbursement policies for such therapies will also have a weighty impact on the market in North America. The rising awareness among patient population towards advanced treatment options will also spur demand for mucopolysaccharidosis treatment market. The presence of significant players and biopharmaceutical companies along with ongoing clinical trials will further augment growth in North America. Europe is predicted to witness high growth during the forecast period owing to the high sales of Elaprase and ALDURAZYME in the region. Asia Pacific is predicted to grow significantly due to launch of novel therapeutics such as Hunterase in Japan. The growing patient population in various countries will enable growth of the market in the region.

The global mucopolysaccharidosis treatment market report focuses and elaborates the definition, types, applications and major players in detail. Deep analysis about mucopolysaccharidosis treatment, competition patterns, enterprise, advantages and disadvantages of enterprise products, industry development trends, regional industrial layout characteristics and macroeconomic policies, industrial policy has also been studied and provided within the synopsis. From raw materials to downstream buyers of this industry has been analyzed scientifically, the feature of product circulation and sales channel is presented as well. This report is aimed at helping companies, investors and potential shareholders along with venture capitalists establish a bird’s eye view prospect of industrial development and characteristics of the market. The report also benefits its readers by providing the unrivalled data in well-organized manner.

List of Key Players Mentioned in the Report:

  • Shire (Takeda Pharmaceutical Company Limited)
  • Denali Therapeutics
  • ArmaGen
  • REGENXBIO Inc.
  • Sangamo Therapeutics
  • BioMarin
  • Lysogene
  • Abeona Therapeutics Inc.
  • Ultragenyx Pharmaceutical
  • Genzyme Corporation
  • Others


Quick Buy Mucopolysaccharidosis Treatment Market Research Report https://www.fortunebusinessinsights.com/checkout-page/102551


Table of Content

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Prevalence of Key Mucopolysaccharidosis Types - by key regions (2018)
    • Pipeline Analysis
    • Key Industry Developments
    • Regulatory Scenario- by Key Regions
    • Overview of Emerging Treatments for Mucopolysaccharidosis
    • Reimbursement Scenario - by Key Regions
  • Global Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Treatment
      • Enzyme Replacement Therapy (ERT)
      • Others
    • Market Analysis, Insights and Forecast – By Disease Type
      • Mucopolysaccharidosis Type I
      • Mucopolysaccharidosis Type II
      • Mucopolysaccharidosis Type IV A
      • Mucopolysaccharidosis Type VI
      • Others
    • Market Analysis, Insights and Forecast – By Route of Administration
      • Intravenous
      • Intracerebroventricular (ICV)
    • Market Analysis, Insights and Forecast – By End User
      • Hospitals
      • Specialty Clinics
      • Others
    • Market Analysis, Insights and Forecast – By Region
      • North America
      • Europe
      • Asia pacific
      • Rest of the World
  • North America Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis – By Treatment
      • Enzyme Replacement Therapy (ERT)
      • Others
    • Market Analysis – By Disease Type
      • Mucopolysaccharidosis Type I
      • Mucopolysaccharidosis Type II
      • Mucopolysaccharidosis Type IV A
      • Mucopolysaccharidosis Type VI
      • Others
    • Market Analysis – By Route of Administration
      • Intravenous
      • Intracerebroventricular (ICV)
    • Market Analysis – By End User
      • Hospitals
      • Specialty Clinics
      • Others
    • Market Analysis – By Country
      • U.S.
      • Canada

Toc Continue…


Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/mucopolysaccharidosis-treatment-market-102551


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com


Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release